These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 22364129)

  • 41. Rheumatoid arthritis in dermatology.
    Hata T; Kavanaugh A
    Clin Dermatol; 2006; 24(5):430-7. PubMed ID: 16966022
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention.
    Snow MH; Mikuls TR
    Curr Opin Rheumatol; 2005 May; 17(3):234-41. PubMed ID: 15838230
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Triggers of Cardiovascular Diseases in Rheumatoid Arthritis.
    Zhang M; Wang M; Tai Y; Tao J; Zhou W; Han Y; Wei Wei ; Wang Q
    Curr Probl Cardiol; 2022 Jun; 47(6):100853. PubMed ID: 34016483
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Cardiovascular Complications of Rheumatoid Arthritis: Prevalence and Pathogenesis].
    Krougly LB; Fomicheva OA; Karpov YA; Popkova TV; Novikova DS; Nasonov EL
    Kardiologiia; 2016 Jun; 56(6):89-95. PubMed ID: 28290854
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis.
    Al-Aly Z; Pan H; Zeringue A; Xian H; McDonald JR; El-Achkar TM; Eisen S
    Transl Res; 2011 Jan; 157(1):10-8. PubMed ID: 21146146
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma.
    Sarzi-Puttini P; Atzeni F; Shoenfeld Y; Ferraccioli G
    Autoimmun Rev; 2005 Mar; 4(3):153-61. PubMed ID: 15823501
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis.
    Barnabe C; Martin BJ; Ghali WA
    Arthritis Care Res (Hoboken); 2011 Apr; 63(4):522-9. PubMed ID: 20957658
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Managing Cardiovascular Disease Risk in Rheumatoid Arthritis: Clinical Updates and Three Strategic Approaches.
    Chodara AM; Wattiaux A; Bartels CM
    Curr Rheumatol Rep; 2017 Apr; 19(4):16. PubMed ID: 28361332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular disease in patients with rheumatoid arthritis.
    Liao KP
    Trends Cardiovasc Med; 2017 Feb; 27(2):136-140. PubMed ID: 27612551
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis.
    Tocci G; Goletti D; Marino V; Matucci A; Milano GM; Cantini F; Scarpa R
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):55-61. PubMed ID: 27924645
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis.
    Baghdadi LR; Woodman RJ; Shanahan EM; Mangoni AA
    PLoS One; 2015; 10(2):e0117952. PubMed ID: 25689371
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Cardiovascular risk in systemic inflammatory diseases].
    Marsico F; Parente A; Paolillo S; Casaretti L; Lo Iudice F; Pirozzi E; Conte S; Iardino E; Gambardella F; Della Ratta GL; Cirillo A; Vitagliano A; Filardi PP
    G Ital Cardiol (Rome); 2013; 14(7-8):517-25. PubMed ID: 23877549
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Atherosclerosis and rheumatoid arthritis].
    Soubrier M; Dougados M
    Rev Med Interne; 2006 Feb; 27(2):125-36. PubMed ID: 16040164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Severe Extraarticular Manifestations in a Community-based Cohort of Patients with Rheumatoid Arthritis: Risk Factors and Incidence in Relation to Treatment with Tumor Necrosis Factor Inhibitors.
    Theander L; Nyhäll-Wåhlin BM; Nilsson JÅ; Willim M; Jacobsson LTH; Petersson IF; Turesson C
    J Rheumatol; 2017 Jul; 44(7):981-987. PubMed ID: 28461642
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiovascular disease in rheumatoid arthritis: Current perspectives on assessing and mitigating risk in clinical practice.
    Giles JT
    Best Pract Res Clin Rheumatol; 2015; 29(4-5):597-613. PubMed ID: 26697769
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis.
    Semb AG; Ikdahl E; Wibetoe G; Crowson C; Rollefstad S
    Nat Rev Rheumatol; 2020 Jul; 16(7):361-379. PubMed ID: 32494054
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiovascular risk and rheumatoid arthritis: from mechanisms of atherosclerosis to therapeutic approach.
    Jurcuţ C; Jurcuţ R; Tănăsescu C
    Rom J Intern Med; 2004; 42(4):659-69. PubMed ID: 16366138
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Marine n-3 fatty acids for cardiovascular risk reduction and disease control in rheumatoid arthritis: "kill two birds with one stone"?
    Rontoyanni VG; Sfikakis PP; Kitas GD; Protogerou AD
    Curr Pharm Des; 2012; 18(11):1531-42. PubMed ID: 22364137
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis.
    Dessein PH; Joffe BI; Singh S
    Arthritis Res Ther; 2005; 7(3):R634-43. PubMed ID: 15899050
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Cardiovascular diseases and rheumatoid arthritis].
    Morović-Vergles J
    Reumatizam; 2010; 57(2):11-5. PubMed ID: 21874999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.